Product Name :
JR14a
Description:
JR14a is a potent thiophene antagonist of human complement C3a receptor. JR14a shows selectivity for the human C3a receptor over C5a receptor. JR14a can suppress C3aR-mediated inflammation.
CAS:
2411440-41-8
Molecular Weight:
533.47
Formula:
C25H26Cl2N4O3S
Chemical Name:
(2S)-2-({5-[bis(4-chlorophenyl)methyl]-3-methylthiophen-2-yl}formamido)-5-[(diaminomethylidene)amino]pentanoic acid
Smiles :
CC1C=C(SC=1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C(C1C=CC(Cl)=CC=1)C1C=CC(Cl)=CC=1
InChiKey:
OHRIKWUZKGNQKQ-IBGZPJMESA-N
InChi :
InChI=1S/C25H26Cl2N4O3S/c1-14-13-20(21(15-4-8-17(26)9-5-15)16-6-10-18(27)11-7-16)35-22(14)23(32)31-19(24(33)34)3-2-12-30-25(28)29/h4-11,13,19,21H,2-3,12H2,1H3,(H,31,32)(H,33,34)(H4,28,29,30)/t19-/m0/s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.{{FGF-8b Protein, Human/Mouse} site|{FGF-8b Protein, Human/Mouse} Biological Activity|{FGF-8b Protein, Human/Mouse} In stock|{FGF-8b Protein, Human/Mouse} manufacturer|{FGF-8b Protein, Human/Mouse} Cancer}
Shelf Life:
≥12 months if stored properly.{{Acetazolamide} web|{Acetazolamide} Bacterial|{Acetazolamide} Biological Activity|{Acetazolamide} References|{Acetazolamide} supplier|{Acetazolamide} Autophagy}
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
JR14a is a potent thiophene antagonist of human complement C3a receptor. JR14a shows selectivity for the human C3a receptor over C5a receptor. JR14a can suppress C3aR-mediated inflammation.PMID:23557924 |Product information|CAS Number: 2411440-41-8|Molecular Weight: 533.47|Formula: C25H26Cl2N4O3S|Chemical Name: (2S)-2-({5-[bis(4-chlorophenyl)methyl]-3-methylthiophen-2-yl}formamido)-5-[(diaminomethylidene)amino]pentanoic acid|Smiles: CC1C=C(SC=1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C(C1C=CC(Cl)=CC=1)C1C=CC(Cl)=CC=1|InChiKey: OHRIKWUZKGNQKQ-IBGZPJMESA-N|InChi: InChI=1S/C25H26Cl2N4O3S/c1-14-13-20(21(15-4-8-17(26)9-5-15)16-6-10-18(27)11-7-16)35-22(14)23(32)31-19(24(33)34)3-2-12-30-25(28)29/h4-11,13,19,21H,2-3,12H2,1H3,(H,31,32)(H,33,34)(H4,28,29,30)/t19-/m0/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|JR14a (0.1 nM-100 μM) inhibits C3a-induced intracellular Ca2+ release in human monocyte-derived macrophages, with an IC50 of 10 nM. JR14a (0.1 nM-100 μM) is metabolically stable to exposure over 1 h to rat liver microsomes. JR14a (0.1 nM-100 μM) inhibits C3a-induced β-hexosaminidase secretion in human LAD2 mast cells, with an IC50 of 8 nM.|In Vivo:|JR14a (10 mg/kg; p.o. 2 h prior) reduces paw swelling by 65% over control at 30 min after agonist injection in acute rat paw model of inflammation and edema. JR14a (1 mg/kg; i.v.) exhibits elimination half-life (191 min), clearance (4.4 mL/min/kg) and AUC (3795 ng•h/mL) in rats. JR14a (10 mg/kg; p.o.) exhibits Cmax (88 ng/mL), Tmax (300 min) and AUC (478 ng•h/mL) in rats.|Products are for research use only. Not for human use.|
